## WHO Prequalification Programme WHO PUBLIC ASSESSMENT REPORT (WHOPAR)

## [CV004 trade name]\*

## dexamethasone phosphate 4 mg/mL solution for injection

[CV004 trade name], manufactured at Farmak JSC, 74 Kyrylivska St., Kyiv, Ukraine, was included in the WHO list of prequalified medicinal products for the management of conditions responsive to parenteral treatment with a potent glucocorticoid on 5 November 2020.

[CV004 trade name] is indicated in a wide range of conditions for its anti-inflammatory and immunosuppressant effects. Detailed information on the use of this product is described in the summary of product characteristics (SmPC), which can be found in this WHOPAR.

The active pharmaceutical ingredient of [CV004 trade name] is dexamethasone phosphate, a glucocorticoid.

The efficacy and safety of dexamethasone is well established based on extensive clinical experience in the treatment of a wide range of conditions. For details on the uses of this product and for side effects and warnings, see Part 4 of this WHOPAR (summary of product characteristics).

On the basis of data submitted and public information on the use of, the team of assessors advised that [CV004 trade name] is of acceptable quality, efficacy and safety to allow inclusion of [CV004 trade name] in the list of prequalified medicinal products.

## **Summary of prequalification status for [CV004 trade name]:**

Initial acceptance	Date	Outcome
Status on PQ list	5 November 2020	listed
Quality	31 October 2020	MR
Bioequivalence	2 November 2020	MR
Safety, efficacy	NA	NA
GMP (re-)inspection		
API	NA	NA
FPP	24 January 2020	MR
GCP/GLP (re-)inspection	NA	NA
API: active pharmaceutical ingredient FPP: finished pharmaceutical product GCP: good clinical practice [quality standard] GLP: good laboratory practice [quality standard]	GMP: good manufacturing practice [quality standard] MR: meets requirements NA: not applicable, not available PQ: prequalification	

The table represents the status of relevant completed activities only.

\_

<sup>\*</sup> Trade names are not prequalified by WHO. This is the national medicines regulatory authority's responsibility. Page 1 of 1